| Abstract |
Objective To observe the clinical effect of edaravone in the treatment of acute cerebral infarction. Methods According to the research purpose, 92 patients with acute cerebral infarction admitted to our hospital from December 2020 to January 2022 were selected as the subjects of this observation. According to the random number table method, all patients were randomly divided into two groups, namely the treatment group and the control group, with 46 patients in each group. The control group only received conventional treatment, while the treatment group was treated with edaravone. The neurological damage and improvement of living ability, the incidence of adverse reactions after treatment and the overall effective rate of treatment were compared between the two groups before and after treatment. Results Before treatment, the difference in NIHSS score and ADL score between the treatment group and the control group was small, and there was no statistical significance (P>0.05). The NIHSS score and ADL score were better than those in the control group, with statistical significance (P<0.05); after treatment, the incidence of adverse reactions in the control group was higher than that in the treatment group, with statistical significance (P<0.05). The total effective rate of treatment was much higher than that of the control group, with statistical significance (P<0.05). Conclusion The clinical effect of edaravone treatment for patients with acute cerebral infarction is ideal, it can effectively relieve the clinical symptoms of patients, reduce the rate of adverse reactions, enhance the ability to recover from nerve damage, inhibit cytotoxicity, and then improve the prognosis of cerebral infarction and improve the ability to live, to improve the treatment effect. Edaravone has high safety and high clinical value.
|